Pre-clinical studies using the MerTK inhibitor BMS-777607, a small molecule inhibitor that also targets the RTKs Met, Ron, Tyro3, and Axl [97], confirmed that efferocytosis can be blocked within highly apoptotic post-lactational mammary tumors [79]. This evidence concerns the gene MERTK and breast cancer.